Novel biomarkers of metastatic cancer

References

• Fidler IJ. Molecular biology of cancer: invasion and metastases. In: Cancer Principles and Practice of Oncology. Devita VT, Hellman, S, Rosenberg SA (Eds). Lippincott-Raven, PA, USA, 135–152 (1997).
   Google Scholar
• Norton L. Metastatic breast cancer: length and quality of life. N. Engl. J. Med.325, 1370–1371 (1991).
   PubMed Web of Science ®Google Scholar
• Sawyers CL. The cancer biomarker problem. Nature452(7187), 548–552 (2008).
   PubMed Web of Science ®Google Scholar
• Ludwig JA, Weinstein JN. Biomarkers in cancer staging, prognosis and treatment selection. Nat. Rev. Cancer5(11), 845–856 (2005).
   PubMed Web of Science ®Google Scholar
• Chambers AF, Groom AC, MacDonald IC. Dissemination and growth of cancer cells in metastatic sites. Nat. Rev. Cancer2, 563–572 (2002).
   PubMed Web of Science ®Google Scholar
• Mundy GR. Metastases to bone: causes, consequences and therapeutic opportunities. Nat. Rev. Cancer2, 584–593 (2002).
   PubMed Web of Science ®Google Scholar
• Poste G and Fidler IJ. The pathogenesis of cancer metastasis. Nature283, 139–146 (1980).
   PubMed Web of Science ®Google Scholar
• Ramaswamy S, Ross KN, Lander ES and Golub TR. A molecular signature of metastasis in primary solid tumors. Nat. Genet.33, 49–54 (2003).
   PubMed Web of Science ®Google Scholar
• Perou CM, Sorlie T, Eisen MB et al. Molecular portraits of human breast tumors. Nature406, 747–752 (2000).
   PubMed Web of Science ®Google Scholar
• Sorlie T, Perou CM, Tibshirani R et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl Acad. Sci. USA98, 10869–10874 (2001).
   PubMed Web of Science ®Google Scholar
• Cardoso F, Castiglione M. Locally recurrent or metastatic breast cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann. Oncol.20(Suppl. 4), 15–18 (2009).
   PubMed Web of Science ®Google Scholar
• Dawood S, Broglio K, Esteva FJ et al. Survival among women with triple receptor-negative breast cancer and brain metastases. Ann. Oncol.20(4), 621–627 (2009).
   PubMed Web of Science ®Google Scholar
• Leyland-Jones B. Human epidermal growth factor receptor 2-positive breast cancer and central nervous system metastases. J. Clin. Oncol.27(31), 5278–5286 (2009).
   PubMed Web of Science ®Google Scholar
• Minn AJ, Gupta GP, Siegel PM et al. Genes that mediate breast cancer metastasis to lung. Nature436(7050), 518–524 (2005).
   PubMed Web of Science ®Google Scholar
• Dowsett M, Dunbier AK. Emerging biomarkers and new understanding of traditional markers in personalized therapy for breast cancer. Clin. Cancer Res.4(24), 8019–26 (2008).
   Web of Science ®Google Scholar
• Paik S, Shak S, Tang G et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N. Engl. J. Med.351(27), 2817–26 (2004).
   PubMed Web of Science ®Google Scholar
• van de Vijver MJ, He YD, van’t Veer LJ et al. A gene-expression signature as a predictor of survival in breast cancer. N. Engl. J. Med.347(25), 1999–2009 (2002).
   PubMed Web of Science ®Google Scholar
• Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat. Rev. Mol. Cell Biol.2(2), 127–137 (2001).
   PubMed Web of Science ®Google Scholar
• Park JW, Neve RM, Szollosi J, Benz CC. Unraveling the biologic and clinical complexities of HER2. Clin. Breast Cancer8(5), 392–401 (2008).
   PubMed Web of Science ®Google Scholar
• Spector NL, Blackwell KL. Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer. J. Clin. Oncol.27(34), 5838–5847 (2009).
   PubMed Web of Science ®Google Scholar
• Gravalos C, Jimeno A. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann. Oncol.19(9), 1523–1529 (2008).
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med.344(11), 783–792 (2001).
   PubMed Web of Science ®Google Scholar
• Dawood S, Broglio K, Buzdar AU, Hortobagyi GN, Giordano SH. Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review. J. Clin. Oncol.28(1), 92–98 (2010).
   PubMed Web of Science ®Google Scholar
• Romond EH, Perez EA, Bryant J et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N. Engl. J. Med.353(16), 1673–1684 (2005).
   PubMed Web of Science ®Google Scholar
• Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N. Engl. J. Med.353(16), 1659–1672 (2005).
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, KangY, Chung H et al. Efficacy results from the ToGA trial: a Phase III study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (GC). J. Clin. Oncol.27(Suppl.), 18s (2009) (Abstract LBA4509).
   Google Scholar
• Harari PM. Epidermal growth factor receptor inhibition strategies in oncology. Endocr. Relat. Cancer11(4), 689–708 (2004).
   PubMed Web of Science ®Google Scholar
• Nicholson RI, Gee JM, Harper ME. EGFR and cancer prognosis. Eur. J. Cancer37(Suppl. 4), S9–S15 (2001).
   PubMedGoogle Scholar
• Rusch VD, Klimstra E, Venkatraman P et al. Over expression of the epidermal growth factor receptor and its ligand transforming growth a is frequent in resectable non-small cell lung cancer but does not predict tumor progression. Clin. Cancer Res.3, 515–522 (1997).
   PubMed Web of Science ®Google Scholar
• Hirsch FR, Varella-Garcia M, Bunn PA Jr et al. Epidermal growth factor receptor in non-small cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J. Clin. Oncol.21, 3798–807 (2003).
   PubMed Web of Science ®Google Scholar
• Govindan R. Cetuximab in advanced non-small cell lung cancer. Clin. Cancer Res.10, 4241s–4244s (2004).
   Web of Science ®Google Scholar
• Pirker R, Pereira JR, Szczesna A et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised Phase III trial. Lancet373(9674), 1525–1531 (2009).
   PubMed Web of Science ®Google Scholar
• Lynch TJ, Patel T, Dreisbach L et al. A randomized multicenter Phase III study of cetuximab (Erbitux) in combination with taxane/carboplatin alone as first-line treatment for patients with advanced/metastatic non-small lung cancer (NSCLC). J. Thorac. Oncol.2, S340–S341 (2007).
   Web of Science ®Google Scholar
• Azzoli CG, Baker S Jr, Temin S et al. American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. J. Clin. Oncol.27(36), 6251–6266 (2009).
   PubMed Web of Science ®Google Scholar
• Pao W, Miller V, Zakowski M et al. EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc. Natl Acad. Sci. USA101, 13306–13311 (2004).
   PubMed Web of Science ®Google Scholar
• Lynch TJ, Bell DW Sordella R et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small cell lung cancer to gefitinib. N. Engl. J. Med.350, 2129–2139 (2004).
   PubMed Web of Science ®Google Scholar
• Coate LE, John T, Tsao MS, Shepherd FA. Molecular predictive and prognostic markers in non-small-cell lung cancer. Lancet Oncol.10(10), 1001–1010 (2009).
   PubMed Web of Science ®Google Scholar
• Herbst RS, Prager D, Hermann R et al. TRIBUTE: a Phase III trial of erlotinib hydrochloride (OSI) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J. Clin. Oncol.23, 5892–5899 (2005).
   PubMed Web of Science ®Google Scholar
• Mok TS, Wu YL, Thongprasert S et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med.361(10), 947–957 (2009).
   PubMed Web of Science ®Google Scholar
• Zhu CQ, Pintilie M, John T et al. Understanding prognostic gene expression signatures in lung cancer. Clin. Lung Cancer10(5), 331–340 (2009).
   PubMed Web of Science ®Google Scholar
• Suda K, Onozato R, Yatabe Y, Mitsudomi T. EGFR T790M mutation: a double role in lung cancer cell survival? J. Thorac. Oncol.4(1), 1–4 (2009).
   PubMed Web of Science ®Google Scholar
• Saltz LB, Meropol NJ, Loehrer PJ Sr, Needle MN, Kopit J, Mayer RJ. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J. Clin. Oncol.22(7), 1201–1208 (2004).
   PubMed Web of Science ®Google Scholar
• Chung KY, Shia J, Kemeny NE et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J. Clin. Oncol.23(9), 1803–1810 (2005).
   PubMed Web of Science ®Google Scholar
• Moroni M, Veronese S, Benvenuti S et al. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol.6(5), 279–286 (2005).
   PubMed Web of Science ®Google Scholar
• Barber TD, Vogelstein B, Kinzler KW, Velculescu VE. Somatic mutations of EGFR in colorectal cancers and glioblastomas. N. Engl. J. Med.351(27), 2883 (2004).
   PubMed Web of Science ®Google Scholar
• Mitchell EP, Hecht JR, Baranda J et al. Panitumumab activity in metastatic colorectal cancer (mCRC) patients (pts) with low or negative tumor epidermal growth factor (EGFr) levels: an updated analysis. J. Clin. Oncol.25(18 Suppl.) (2007) (Abstract 4081).
   Google Scholar
• Siena S, Sartore-Bianchi A, Di Nicolantonio F, Balfour J, Bardelli A. Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer. J. Natl Cancer Inst.101(19), 1308–1324 (2009).
   PubMedGoogle Scholar
• Bos JL. Ras oncogenes in human cancer: a review. Cancer Res.49(17), 4682–4689 (1989).
   PubMed Web of Science ®Google Scholar
• McCubrey JA, Steelman LS, Abrams SL et al. Roles of the RAF/MEK/ERK and PI3k/PTEN/AKT pathways in malignant transformation and drug resistance. Adv. Enzyme Regul.46(1), 249–279 (2006).
   PubMedGoogle Scholar
• Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell61(5), 759–767 (1990).
   PubMed Web of Science ®Google Scholar
• Barault L, Veyrie N, Jooste V et al. Mutations in the RAS–MAPK, PI(3)K (phosphatidylinositol-3-OH kinase) signaling network correlate with poor survival in a population-based series of colon cancers. Int. J. Cancer122(10), 2255–2259 (2008).
   PubMed Web of Science ®Google Scholar
• Huncharek M, Muscat J, Geschwind JF. K-ras oncogene mutation as a prognostic marker in non-small cell lung cancer: a combined analysis of 881 cases. Carcinogenesis20(8), 1507–1510 (1999).
   PubMed Web of Science ®Google Scholar
• Amado RG, Wolf M, Peeters M et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J. Clin. Oncol.26, 1626–1634 (2008).
   PubMed Web of Science ®Google Scholar
• Bokemeyer C, Bondarenko I, Hartmann JT et al. KRAS status and efficacy of first-line treatment of patients with metastatic colorectal (metastatic CRC) with FOLFOX with or without cetuximab: the OPUS experience. J. Clin. Oncol.26(Suppl.), 178s (2008) (Abstract 4000).
   Web of Science ®Google Scholar
• Karapetis CS, Khambata-Ford S, Jonker DJ et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N. Engl. J. Med.359, 1757–1765 (2008)
   PubMed Web of Science ®Google Scholar
• Punt CJ, Tol J, Rodenburg CJ et al. Randomized Phase III study of capecitabine, oxaliplatin, and bevacizumab with or without cetuximab in advanced colorectal cancer (ACC), the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). J. Clin. Oncol.26(Suppl.), 180s (2008) (Abstract LBA4011).
   Web of Science ®Google Scholar
• Van Cutsem E, Lang I, D’haens G et al. KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (metastatic CRC) treated with FOLFIRI with or without cetuximab: The CRYSTAL experience. J. Clin. Oncol.26(Suppl.), 5s (2008) (Abstract 2).
   Web of Science ®Google Scholar
• Allegra CJ, Jessup JM, Somerfield MR et al. American Society of Clinical Oncology provisional clinical opinion: testing for KRASgene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J. Clin. Oncol.27(12), 2091–2096 (2009).
   PubMed Web of Science ®Google Scholar
• Di Nicolantonio F, Martini M, Molinari F et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J. Clin. Oncol.26(35), 5705–5712 (2008).
   PubMed Web of Science ®Google Scholar
• Tol J, Nagtegaal ID, Punt CJ. BRAF mutation in metastatic colorectal cancer. N. Engl. J. Med.361(1), 98–99 (2009).
   PubMed Web of Science ®Google Scholar
• Frattini M, Saletti P, Romagnani E et al. PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients. Br. J. Cancer97(8), 1139–1145 (2007).
   PubMed Web of Science ®Google Scholar
• Sartore-Bianchi A, Martini M, Molinari F et al. PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. Cancer Res.69(5), 1851–1857 (2009).
   PubMed Web of Science ®Google Scholar
• Elshimali YI, Grody WW. The clinical significance of circulating tumor cells in the peripheral blood. Diagn. Mol. Pathol.15(4), 187–194 (2006).
   PubMedGoogle Scholar
• Thiery JP. Epithelial–mesenchymal transitions in tumour progression. Nat. Rev. Cancer2(6), 442–454 (2002).
   PubMed Web of Science ®Google Scholar
• Hugo H, Ackland ML, Blick T et al. Epithelial – mesenchymal and mesenchymal – epithelial transitions in carcinoma progression. J. Cell Physiol.213(2), 374–383 (2007).
   PubMed Web of Science ®Google Scholar
• Dotan E, Cohen SJ, Alpaugh KR, Meropol NJ. Circulating tumor cells: evolving evidence and future challenges. Oncologist14(11), 1070–1082 (2009).
   PubMed Web of Science ®Google Scholar
• Allard WJ, Matera J, Miller MC et al. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin. Cancer Res.10, 6897–6904 (2004).
   PubMed Web of Science ®Google Scholar
• Cristofanilli M, Budd GT, Ellis M et al. Circulating tumor cells predict progression free survival and overall survival in metastatic breast cancer. N. Engl. J. Med.351, 781–791 (2004).
   PubMed Web of Science ®Google Scholar
• Cristofanilli M, Broglio KR, Guarneri V et al. Circulating tumor cells in metastatic breast cancer: biologic staging beyond tumor burden. Clin. Breast Cancer6, 471–479 (2007).
   Google Scholar
• Hayes DF, Cristofanilli M, Budd GT et al. Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival. Clin. Cancer Res.12(14), 4218–4224 (2006).
   PubMed Web of Science ®Google Scholar
• Budd GT, Cristofanilli M, Eillis MJ et al. Circulating tumor cells versus imaging – predicting overall survival in metastatic breast cancer. Clin. Cancer Res.12(21), 6403–6409 (2006).
   PubMed Web of Science ®Google Scholar
• Dawood S, Broglio K, Valero V et al. Circulating tumor cells in metastatic breast cancer: from prognostic stratification to modification of the staging system? Cancer113(9), 2422–2430 (2008).
   PubMed Web of Science ®Google Scholar
• Pestrin M, Bessi S, Galardi F et al. Correlation of HER2 status between primary tumors and corresponding circulating tumor cells in advanced breast cancer patients. Breast Cancer Res. Treat.118(3), 523–530 (2009).
   PubMed Web of Science ®Google Scholar
• Fehm T, Becker S, Duerr-Stoerzer S et al. Determination of HER2 status using both serum HER2 levels and circulating tumor cells in patients with recurrent breast cancer whose primary tumor was HER2 negative or of unknown HER2 status. Breast Cancer Res.9(5), R74 (2007).
   PubMed Web of Science ®Google Scholar
• Meng S, Tripathy D, Shete S et al. HER-2 gene amplification can be acquired as breast cancer progresses. Proc. Natl Acad. Sci. USA101(25), 9393–9398 (2004).
   PubMed Web of Science ®Google Scholar
• Moreno JG, Miller MC, Gross S, Allard WJ, Gomella LG, Terstappen LW. Circulating tumor cells predict survival in patients with metastatic prostate cancer. Urology65(4), 713–718 (2005).
   PubMed Web of Science ®Google Scholar
• Danila DC, Heller G, Gignac GA et al. Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer. Clin. Cancer Res.13(23), 7053–7058 (2007).
   PubMed Web of Science ®Google Scholar
• Shaffer DR, Leversha MA, Danila DC et al. Circulating tumor cell analysis in patients with progressive castration-resistant prostate cancer. Clin. Cancer Res.13(7), 2023–2029 (2007).
   PubMed Web of Science ®Google Scholar
• Cohen SJ, Alpaugh RK, Gross S et al. Isolation and characterization of circulating tumor cells in patients with metastatic colorectal cancer. Clin. Colorectal Cancer6(2), 125–132 (2006).
   PubMed Web of Science ®Google Scholar
• Cohen SJ, Punt CJ, Iannotti N. Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J. Clin. Oncol.26(19), 3213–3221 (2008).
   PubMed Web of Science ®Google Scholar
• Tol J, Koopman M, Miller MC et al. Circulating tumour cells early predict progression-free and overall survival in advanced colorectal cancer patients treated with chemotherapy and targeted agents. Ann. Oncol.21(5), 1006–1012 (2010).
   PubMed Web of Science ®Google Scholar
• Lee Y, Ahn C, Han J et al. The nuclear RNase III Drosha initiates microRNA processing. Nature425(6956), 415–419 (2003).
   PubMed Web of Science ®Google Scholar
• Hutvágner G, McLachlan J, Pasquinelli AE, Bálint E, Tuschl T, Zamore PD. A cellular function for the RNA-interference enzyme Dicer in the maturation of the let-7 small temporal RNA. Science293(5531), 834–838 (2001).
   PubMed Web of Science ®Google Scholar
• Cho WC. MicroRNAs in cancer – from research to therapy. Biochim. Biophys. Acta1805(2), 209–217 (2010).
   PubMed Web of Science ®Google Scholar
• Cho WC. MicroRNAs: potential biomarkers for cancer diagnosis, prognosis and targets for therapy. Int. J. Biochem Cell Biol. DOI:10.1016/j.biocel.2009.12.014 (2009) (Epub ahead of print).
   Google Scholar
• Ma L, Teruya-Feldstein J, Weinberg RA. Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature449(7163), 682–688 (2007).
   PubMed Web of Science ®Google Scholar
• Tavazoie SF, Alarcón C, Oskarsson T et al. Endogenous human microRNAs that suppress breast cancer metastasis. Nature451(7175), 147–152 (2008).
   PubMed Web of Science ®Google Scholar
• Stenvang J, Silahtaroglu AN, Lindow M, Elmen J, Kauppinen S. The utility of LNA in microRNA-based cancer diagnostics and therapeutics. Semin. Cancer Biol.18(2), 89–102 (2008).
   PubMed Web of Science ®Google Scholar
• Rosenfeld N, Aharonov R, Meiri E et al. MicroRNAs accurately identify cancer tissue origin. Nat. Biotechnol.26(4), 462–469 (2008).
   PubMed Web of Science ®Google Scholar
• Pimiento JM, Teso D, Malkan A, Dudrick SJ, Palesty JA. Cancer of unknown primary origin: a decade of experience in a community-based hospital. Am. J. Surg.194(6), 833–837 (2007).
   PubMed Web of Science ®Google Scholar
• Merritt WM, Lin YG, Han LY et al. Dicer, Drosha, and outcomes in patients with ovarian cancer. N. Engl. J. Med.359(25), 2641–2650 (2008).
   PubMed Web of Science ®Google Scholar
• Karube Y, Tanaka H, Osada H et al. Reduced expression of Dicer associated with poor prognosis in lung cancer patients. Cancer Sci.96(2), 111–115 (2005).
   PubMed Web of Science ®Google Scholar
• Chan JA, Krichevsky AM, Kosik KS. MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. Cancer Res.65(14), 6029–6033 (2005).
   PubMed Web of Science ®Google Scholar
• Si ML, Zhu S, Wu H, Lu Z, Wu F, Mo YY. miR-21-mediated tumor growth. Oncogene26(19), 2799–27803 (2007).
   PubMed Web of Science ®Google Scholar
• Ebert MS, Neilson JR, Sharp PA. MicroRNA sponges: competitive inhibitors of small RNAs in mammalian cells. Nat. Methods4(9), 721–726 (2007).
   PubMed Web of Science ®Google Scholar
• Kota J, Chivukula RR, O’Donnell KA et al. Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell137(6), 1005–1017 (2009).
   PubMed Web of Science ®Google Scholar
• Laurent-Puig P, Cayre A, Manceau G et al. Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. J. Clin. Oncol.27(35), 5924–5930 (2009).
   PubMed Web of Science ®Google Scholar
• Guix M, Aura CM, Jimenez J et al. Lapatinib is active in patients with HER2-amplified breast tumors expressing p95HER2. San Antonio Breast Cancer Symposium San Antonio, TX, USA 10–14 December 2008 (Abstract 708).
   Google Scholar